Novel contraceptive development and treatments of disease is a Research Project for the Research Group, under the Novel contraceptive development and treatments of disease.
- Blocking sexually transmitted infections and pregnancy using nanoparticles: a novel contraceptive strategy
- Targeted treatment of the placenta for the treatment of pregnancy disorders
In a world first, our team has demonstrated that pharmacologically targeting endometrial factors totally prevents pregnancy. Vaginal delivery has been shown to reduce the uterine side-effects associated with delivery of contraception via injection. We are working with US collaborators to conduct a series of pre-clinical trials of a vaginally-applied non-hormonal contraceptive based on a molecules identified by our team as capable of preventing pregnancy in mice.
Effective contraception is vital to the health and wellbeing of women. Between 1995-2000, more than 700, 000 women died as a result of causes directly associated with unintended pregnancy. More than 400,000 of these women died from unsafe abortions. For many women, existing contraceptives are either unacceptable or not available, and as a result are not used. In the face of these statistics, the development of alternative contraceptives remains vital.
We are currently working with US collaborators to trial vaginally-applied sustained release nanofibres to block pregnancy and sexually transmitted infections including HIV.
Similarly, this method could be applied to target placental cells and cure placental disorders of pregnancy such as preeclampsia.
University of Missouri
University of Melbourne
The Walter and Eliza Hall Institute